Trilab Health announces R&D partnership with ThermoFischer
Chicago, Aug 18th, 2022 – Trilab Health, having a longstanding relationship with ThermoFischer Scientific, announced a strategic R&D partnership for the development of more specific and sensitive testing processes within wound care and women’s health testing. Trilab is developing tests that will aid in the diagnostics of Sexually Transmitted, Urinary Tract and Wound Care infections along with Antibiotic Resistance detections.
New testing modality uses proprietary techniques and methods and offers clinicians a 24hr turnaround alternative to the traditional culture and sensitivity testing that can take up to a week. It also offers a much higher degree of Sensitivity and Specificity in both organism and antibiotic resistances identification that will play a significant role in the enhancement of patient care and clinical outcomes.
Trilab Health will be holding information sessions so please email firstname.lastname@example.org for any questions or details on how to attend a information session.
Waltham, Ma based Thermo Fisher Scientific, Inc. manufactures scientific instruments, consumables, and chemicals. The Company offers analytical instruments, laboratory equipment, software, services, consumables, reagents, chemicals, and supplies to pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions, and government agencies.
Founded by physicians with a healthcare focus, Chicago Based Trilab Health, looks to bridge gaps between diagnostics, patient care and clinical outcomes. We deliver quantitative urine drug testing, customized medication monitoring, high complexity molecular testing and personalized education along with support services to physicians and their patients.
For Release 9am Aug 25, 2022
Press Release Identifier: KA082522